Global Human Rotavirus Vaccine Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Human Rotavirus Vaccine Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Rotavirus vaccine is used to protect against rotavirus infections which cause severe diarrhoea among young children. Symptoms of rotavirus infection include severe diarrhoea, vomiting, fever, and abdominal pain which can result in disease.
Human Rotavirus Vaccine report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Human Rotavirus Vaccine market is projected to reach US$ 10360 million in 2034, increasing from US$ 6753.8 million in 2022, with the CAGR of 6.2% during the period of 2024 to 2034. Demand from Hospitals & Clinics and Academic And Research are the major drivers for the industry.
Rotavirus vaccine is administered by mouth and requires two or three doses starting around six weeks of age. The vaccine first became available in the United States in 2006.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Human Rotavirus Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Bharat Biotech
Merck
GlaxoSmithKline
Segment by Type
Rotarix
RotaTeq
Rotavac
Rotavin-M1
Lanzhou lamb
Others
Hospitals & Clinics
Academic And Research
Others
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Human Rotavirus Vaccine market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Human Rotavirus Vaccine, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Human Rotavirus Vaccine industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Human Rotavirus Vaccine in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Human Rotavirus Vaccine introduction, etc. Human Rotavirus Vaccine Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Human Rotavirus Vaccine market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Human Rotavirus Vaccine report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Human Rotavirus Vaccine market is projected to reach US$ 10360 million in 2034, increasing from US$ 6753.8 million in 2022, with the CAGR of 6.2% during the period of 2024 to 2034. Demand from Hospitals & Clinics and Academic And Research are the major drivers for the industry.
Rotavirus vaccine is administered by mouth and requires two or three doses starting around six weeks of age. The vaccine first became available in the United States in 2006.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Human Rotavirus Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Bharat Biotech
Merck
GlaxoSmithKline
Segment by Type
Rotarix
RotaTeq
Rotavac
Rotavin-M1
Lanzhou lamb
Others
Segment by Application
Hospitals & Clinics
Academic And Research
Others
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Human Rotavirus Vaccine market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Human Rotavirus Vaccine, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Human Rotavirus Vaccine industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Human Rotavirus Vaccine in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Human Rotavirus Vaccine introduction, etc. Human Rotavirus Vaccine Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Human Rotavirus Vaccine market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.